The prevention of brain infarction in patients with atrial fibrillation

Brain and Nerve

Volumn 59, Issue 1, 2007, Pages 53-58

  Ogata, Toshiyasu ^a   Yasaka, Masahiro ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Anticoagulation; NVAF; PT INR

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; BRAIN INFARCTION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; NEUROLOGIC DISEASE; PARTIAL THROMBOPLASTIN TIME; PROPHYLAXIS; PROTHROMBIN TIME; REVIEW; RISK FACTOR; STROKE; AGE; ATRIAL FIBRILLATION; CEREBRAL INFARCTION; CLINICAL TRIAL (TOPIC); COMPLICATION; HEART RATE; META ANALYSIS (TOPIC); PATIENT EDUCATION; PRACTICE GUIDELINE; TOOTH EXTRACTION;

AGE FACTORS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBRAL INFARCTION; CLINICAL TRIALS; HEART RATE; HUMANS; META-ANALYSIS; PATIENT EDUCATION; PRACTICE GUIDELINES; TOOTH EXTRACTION; WARFARIN; CLINICAL TRIALS AS TOPIC; META-ANALYSIS AS TOPIC; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC;

EID: 33846558875     PISSN: 00068969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Japanese source
2. Japanese source
3. Vascular Lab 2: 169-178, 2005
4. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA 285: 2370-2375, 2001
5. Japanese source
6. Japanese source
7. Yasaka M, Yamaguchi T, Miyashita T, Park YD, Sawada T, Omae T: Predisposing factors of recurrent embolization in cardiogenic cerebral embolism. Stroke 21: 1000-1007, 1990
8. Japanese source
9. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347: 1825-1833, 2002
10. Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T, Okumura K, Kato T, Kamakura S, Kumagai K, Kurachi Y, Kodama I, Koretsune Y, Saikawa T, Sakurai M, Sugi K, Nakaya H, Nakayama T, Hirai M, Fukatani M, Mitamura H, Yamazaki T: Investigation of the optimal treatment strategy for atrial fibrillation in japan. Circ J 67: 738-741, 2003
11. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 131: 492-501, 1999
12. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ: Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 429S-456S, 2004
13. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson KA, Bass EB: Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med 15: 56-67, 2000
14. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, Fukuyama T, Doi Y, Mochizuki S, Izumi T, Takekoshi N, Yoshida K, Hiramori K, Origasa H, Uchiyama S, Matsumoto M, Yamaguchi T, Hori M: Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan atrial fibrillation stroke trial. Stroke 37: 447-451, 2006
15. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B: Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 288: 2441-2448, 2002
16. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (active w): A randomised controlled trial. Lancet 367: 1903-1912, 2006
17. Yamaguchi T: Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: A multicenter, prospective, randomized trial. Japanese nonvalvular atrial fibrillation-embolism secondary prevention cooperative study group. Stroke 31: 817-821, 2000
18. Yasaka M, Minematsu K, Yamaguchi T: Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 40: 1183-1188, 2001
19. Japanese Circulation Journal 65: 979-998, 2001
20. Japanese source
21. Stroke prevention in atrial fibrillation iii randomised clinical trial: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Lancet 348: 633-638, 1996
22. Analysis of pooled data from five randomized controlled trials. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 154: 1449-1457, 1994
23. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL: Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol 35: 183-187, 2000
24. Japanese source
25. Japanese source
26. Yasaka M, Naritomi H, Minematsu K: Ischemic stroke associated with brief cessation of warfarin, Thromb Res 118: 290-293, 2006